Comparison of three-day and five-day courses of azithromycin in the treatment of atypical pneumonia - PubMed (original) (raw)
Clinical Trial
. 1991 Oct;10(10):877-80.
doi: 10.1007/BF01975847.
Affiliations
- PMID: 1662637
- DOI: 10.1007/BF01975847
Clinical Trial
Comparison of three-day and five-day courses of azithromycin in the treatment of atypical pneumonia
S Schönwald et al. Eur J Clin Microbiol Infect Dis. 1991 Oct.
Abstract
This open, randomised clinical study, conducted from June 1988 to December 1989, included 84 patients with clinical and radiological findings of atypical pneumonia. All patients were treated with a total dose of 1.5 g azithromycin, a new azalide antibiotic. In Group I, azithromycin was administered for three days (500 mg once daily). In Group II, azithromycin was administered for five days (250 mg b.i.d. on day 1, followed by 250 mg once daily on days 2 to 5). Causative pathogens were identified by serological methods. Of the 41 patients in Group I, Mycoplasma pneumoniae, Chlamydia psittaci and Coxiella burnetti were identified in 19, 4 and 3 patients, respectively. In Group II there were 43 patients; Mycoplasma pneumoniae was identified in 24, Chlamydia psittaci in 4 and Coxiella burnetti in 3. Only patients with known causative pathogens were included in the evaluation of clinical efficacy. All patients were clinically cured by day 5; most of the patients became afebrile within 48 h of starting treatment. Side effects were observed in one patient in Group I and in one patient in Group II. The results suggest that a 1.5 g total dose of azithromycin is equally effective when administered as a three- or five-day regimen for the treatment of atypical pneumonia.
Similar articles
- Three-day azithromycin compared with ten-day roxithromycin treatment of atypical pneumonia.
Schönwald S, Barsić B, Klinar I, Gunjaca M. Schönwald S, et al. Scand J Infect Dis. 1994;26(6):706-10. doi: 10.3109/00365549409008639. Scand J Infect Dis. 1994. PMID: 7747094 Clinical Trial. - Comparison of azithromycin and erythromycin in the treatment of atypical pneumonias.
Schönwald S, Gunjaca M, Kolacny-Babić L, Car V, Gosev M. Schönwald S, et al. J Antimicrob Chemother. 1990 Jan;25 Suppl A:123-6. doi: 10.1093/jac/25.suppl_a.123. J Antimicrob Chemother. 1990. PMID: 2154431 Clinical Trial. - Safety and efficacy of azithromycin in the treatment of community-acquired pneumonia in children.
Harris JA, Kolokathis A, Campbell M, Cassell GH, Hammerschlag MR. Harris JA, et al. Pediatr Infect Dis J. 1998 Oct;17(10):865-71. doi: 10.1097/00006454-199810000-00004. Pediatr Infect Dis J. 1998. PMID: 9802626 Clinical Trial. - Atypical pneumonia.
Martin RE, Bates JH. Martin RE, et al. Infect Dis Clin North Am. 1991 Sep;5(3):585-601. Infect Dis Clin North Am. 1991. PMID: 1955701 Review. - Azithromycin in the treatment of uncomplicated genital chlamydial infections.
Stamm WE. Stamm WE. Am J Med. 1991 Sep 12;91(3A):19S-22S. doi: 10.1016/0002-9343(91)90396-f. Am J Med. 1991. PMID: 1656737 Review.
Cited by
- Clinical Characteristics of Macrolide-Refractory Mycoplasma pneumoniae Pneumonia in Korean Children: A Multicenter Retrospective Study.
Choi YJ, Chung EH, Lee E, Kim CH, Lee YJ, Kim HB, Kim BS, Kim HY, Cho Y, Seo JH, Sol IS, Sung M, Song DJ, Ahn YM, Oh HL, Yu J, Jung S, Lee KS, Lee JS, Jang GC, Jang YY, Chung HL, Choi SM, Han MY, Shim JY, Kim JT, Kim CK, Yang HJ, Suh DI. Choi YJ, et al. J Clin Med. 2022 Jan 8;11(2):306. doi: 10.3390/jcm11020306. J Clin Med. 2022. PMID: 35054002 Free PMC article. - Short- vs long-course antibiotic therapy for pneumonia: a comparison of systematic reviews and guidelines for the SIMI Choosing Wisely Campaign.
Furlan L, Erba L, Trombetta L, Sacco R, Colombo G, Casazza G, Solbiati M, Montano N, Marta C, Sbrojavacca R, Perticone F, Corazza GR, Costantino G. Furlan L, et al. Intern Emerg Med. 2019 Apr;14(3):377-394. doi: 10.1007/s11739-018-1955-2. Epub 2018 Oct 8. Intern Emerg Med. 2019. PMID: 30298412 - Rapid Detection of the Macrolide Sensitivity of Pneumonia-Causing Mycoplasma pneumoniae Using Quenching Probe Polymerase Chain Reaction (GENECUBE®).
Ito Y, Iwashima S, Hayano S, Nishio T, Shiozawa R, Yata S, Kubota T, Kubota A, Uemura K. Ito Y, et al. Mol Diagn Ther. 2018 Dec;22(6):737-747. doi: 10.1007/s40291-018-0360-x. Mol Diagn Ther. 2018. PMID: 30259422 - Guideline for Antibiotic Use in Adults with Community-acquired Pneumonia.
Lee MS, Oh JY, Kang CI, Kim ES, Park S, Rhee CK, Jung JY, Jo KW, Heo EY, Park DA, Suh GY, Kiem S. Lee MS, et al. Infect Chemother. 2018 Jun;50(2):160-198. doi: 10.3947/ic.2018.50.2.160. Infect Chemother. 2018. PMID: 29968985 Free PMC article. Review. - From Erythromycin to Azithromycin and New Potential Ribosome-Binding Antimicrobials.
Jelić D, Antolović R. Jelić D, et al. Antibiotics (Basel). 2016 Sep 1;5(3):29. doi: 10.3390/antibiotics5030029. Antibiotics (Basel). 2016. PMID: 27598215 Free PMC article. Review.
References
- Antimicrob Agents Chemother. 1987 Dec;31(12):1939-47 - PubMed
- Med Clin North Am. 1987 Nov;71(6):1147-54 - PubMed
- J Antimicrob Chemother. 1990 Jan;25 Suppl A:123-6 - PubMed
- J Antimicrob Chemother. 1988 Jul;22 Suppl B:145-53 - PubMed
- J Antimicrob Chemother. 1990 Jan;25 Suppl A:73-82 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical